Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
January 9, 20128m 55s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors.